TP53 mutations in MCL: More therapy is not better

Abstract

In this issue of Blood, Eskelund et al identify a high-risk group of patients with mantle cell lymphoma (MCL) who do not experience prolonged survival despite the use of modern, cytarabine-containing induction therapy followed by autologous stem cell transplantation.